Clinical Trial Update: Suprachoroidal Triamcinolone Acetonide in Harada's Retinal Detachment [Phase 2, Phase 3]

View source ↗

Summary

Phase 2/3 trial update evaluating suprachoroidal triamcinolone acetonide for Vogt-Koyanagi-Harada disease has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Vogt-koyanagi-harada Disease

Drugs mentioned

• Suprachoroidal triamcinolone acetonide (triamcinolone acetonide)

Snippet

Sponsor: Benha University | Conditions: Vogt Koyanagi Harada Disease | Phase 2, Phase 3 | Status: COMPLETED